{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:46:41Z","timestamp":1792057601919,"version":"4.4.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T00:00:00Z","timestamp":1668384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The combination antiretroviral bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) is a single-tablet, once-daily regimen used in individuals living with HIV; however, its use in the context of renal impairment is uncertain. We report 6 patient cases of BIC\/FTC\/TAF utilization in individuals with HIV with end-stage renal disease (ESRD) requiring long-term hemodialysis (HD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>These case reports describe the utilization of BIC\/FTC\/TAF in individuals with HIV who require chronic HD, the laboratory parameters measured, and patient-reported quality of life and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Utilization of BIC\/FTC\/TAF appears to be an option for individuals with HIV who have ESRD and require long-term HD. This regimen allows for once-daily dosing, elimination of potential serious drug interactions, and simplified patient ART regimens in our patient subset.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac339","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T11:29:00Z","timestamp":1668425340000},"page":"e92-e97","source":"Crossref","is-referenced-by-count":5,"title":["Utilization of bictegravir\/emtricitabine\/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis"],"prefix":"10.1093","volume":"80","author":[{"given":"Eric F","family":"Sidman","sequence":"first","affiliation":[{"name":"Upstate University Hospital , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M","family":"Ondrush","sequence":"additional","affiliation":[{"name":"The Mount Sinai Hospital , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"issue":"1","key":"2023041907545183100_CIT0001","first-page":"13","article-title":"Kidney disease and HIV infection","volume":"25","author":"Wyatt","year":"2017","journal-title":"Top Antivir Med"},{"issue":"1","key":"2023041907545183100_CIT0002","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ackd.2009.08.013","article-title":"The treatment of HIV-associated nephropathy","volume":"17","author":"Kalayjian","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"2023041907545183100_CIT0003","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1086\/503566","article-title":"HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy","volume":"42","author":"Roling","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2023041907545183100_CIT0004","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services."},{"key":"2023041907545183100_CIT0005","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(18)30296-0","article-title":"Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial","volume":"6","author":"Eron","year":"2019","journal-title":"Lancet HIV"},{"key":"2023041907545183100_CIT0006","author":"Biktarvy.","year":"2018"},{"issue":"suppl 1","key":"2023041907545183100_CIT0007","doi-asserted-by":"crossref","first-page":"S529","DOI":"10.1093\/ofid\/ofaa439.1188","article-title":"A daily single tablet regimen (STR) of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in virologically-suppressed adults living with HIV and end stage renal disease on chronic hemodialysis","volume":"7","author":"Eron","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023041907545183100_CIT0008","author":"Biktarvy.","year":"2020"},{"issue":"2","key":"2023041907545183100_CIT0009","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/0956462418800865","article-title":"Abacavir\/lamivudine\/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis","volume":"30","author":"Michienzi","year":"2019","journal-title":"Int J STD AIDS"},{"key":"2023041907545183100_CIT0010","author":"Ziagen.","year":"2012"},{"key":"2023041907545183100_CIT0011","article-title":"Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV (PLWH) within the RESPOND cohort consortium","author":"Jaschinski","year":"2021"},{"issue":"2","key":"2023041907545183100_CIT0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2019060574","article-title":"Incident hospitalization with major cardiovascular diseases and subsequent risk of ESKD: implications for cardiorenal syndrome","volume":"31","author":"Ishigami","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2023041907545183100_CIT0013","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2023041907545183100_CIT0014","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12160-016-9827-3","article-title":"Barriers to HIV medication adherence as a function of regimen simplification","volume":"51","author":"Chen","year":"2017","journal-title":"Ann Behav Med"},{"issue":"4","key":"2023041907545183100_CIT0015","first-page":"242","article-title":"Single- versus multiple-tablet HIV regimens: adherence and hospitalization risks","volume":"22","author":"Sutton","year":"2016","journal-title":"Am J Manag Care"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac339\/47685890\/zxac339.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/9\/e92\/49935663\/zxac339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/9\/e92\/49935663\/zxac339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:55:47Z","timestamp":1681890947000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/9\/e92\/6827164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,11,14]]},"published-print":{"date-parts":[[2023,4,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac339","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,11,14]]}}}